Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Donafenib

Research Leaders

5 sponsors active, led by Tianjin Medical University Eye Hospital

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04962958Phase 2Completed

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

NCT06175676Phase 1Completed

Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis

Showing all 2 trials

Research Network

Common Treatments

  • Donafenib1
  • Gelatin Sponge Sheet1
  • Hepatic Arterial Infusion Chemotherapy1
  • Fluorouracil1
  • Hydroxybutyl Chitosan1

Active Sponsors

  • Tianjin Medical University Eye Hospital1
  • The Second Affiliated Hospital of Harbin Medical University1
  • Huashan Hospital1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Meng Chao Hepatobiliary Hospital of Fujian Medical University1

Top Investigators

  • Lei Zhang, PhD1

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Zhu Li min1

    Tianjin medical university eye hosipital

Related Conditions

  • Digestive System Neoplasms1
  • Liver Neoplasms1
  • Oxaliplatin1
  • Carcinoma Hepatocellular1
  • Dacryocystorhinostomy1

Activity Timeline